|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Carcinoma of lung
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer TCGA data validated these findings and unveiled overlap of FGFR1 mRNA positivity with KRAS and PIK3CA mutations.
|
24771645 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation and amplification in human lung cancer.
|
17803655 |
2007 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations have been associated with poor prognosis in patients with colorectal or lung cancer.
|
23532889 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA gene encoding a catalytic subunit of the phosphatidylinositol-3-kinase (PI3K) is mutated and/or amplified in various neoplasia, including lung cancer.
|
24533074 |
2014 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
|
23728071 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined.
|
22363436 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activation to a large extent of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and mutations in the p53 gene are involved in lung cancer therapeutic resistance.
|
20811722 |
2010 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Additionally, Aclidinium Bromide suppressed the PI3K/AKT signaling pathway in lung cancer A549 cells.
|
31128006 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer.
|
29864375 |
2018 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of these results suggested that the lncRNA FER1L4 suppressed cell proliferation and metastasis by inhibiting the PI3K/Akt signaling pathway in lung cancer.
|
31115514 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway.
|
29328421 |
2018 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
cIAP2 upregulated by E6 via EGFR/PI3K/AKT cascades may contribute to cisplatin resistance, revealing that the EGFR or PI3K inhibitor combined with cisplatin may improve the chemotherapeutic efficacy in HPV-infected lung cancer.
|
20959404 |
2010 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
|
29961813 |
2018 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Co-mutations in <i>TP53</i> and the <i>PI3K/AKT/mTOR</i> pathway confer additional resistance to anti-HER2 treatments in lung cancer.
|
31748336 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
|
24743704 |
2014 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combined TAE684 with PI3K inhibitor synergistically inhibited the proliferation of EML4-ALK-positive cells in vitro and significantly suppressed the growth of H2228 xenografts in vivo, suggesting the potential clinical application of such combinatorial therapy regimens in patients with EML4-ALK positive lung cancer.
|
24972969 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
|
27121230 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pro-growth, pro-survival signaling pathways.
|
25524703 |
2015 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Compared with those in the control group, expression of PI3K and Akt in the lung cancer cells H1299 after EGCG treatment showed no significant differences (p>0.05), while expression levels of p-PI3K and p-Akt were significantly reduced (p<0.05).
|
30058690 |
2018 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.
|
29504919 |
2018 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Consistently, DOK7V1 overexpression in lung cancer cells suppressed the phosphoinositide 3‑kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathways, but activated the focal adhesion kinase (FAK)/paxillin signaling pathway.
|
30431081 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Cotransfection of the constitutively active mutant Rac-1 (Val12), an upstream activator of JNK, abrogated Deltap85-induced lung cancer cell death, whereas constitutively active mutant mitogen-activated protein kinase kinase (MKK)-1 (R4F) did not.
|
12714585 |
2003 |